Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 18 2022 - 6:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
January 14, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk announces settlement of securities lawsuit in Denmark
Bagsværd,
Denmark, 14 January 2022 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark
filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will
be made by Novo Nordisk to the plaintiffs.
The lawsuit was filed by a number of shareholders and alleged
that Novo Nordisk had made misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the
US. The original claim was for a total amount of DKK 11,785,192,218.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company,
founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such
as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines
and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products
in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange
(NVO).
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 3079 3883
|
mkd@novonordisk.com
|
Michael Bachner (US)
|
+1 609 664 7308
|
mzyb@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
David Heiberg Landsted
|
+45 3077 6915
|
dhel@novonordisk.com
|
Mark Joseph Root (US)
|
+1 848 213 3219
|
mjhr@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 02 / 2022
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: January 14, 2022
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024